Mangoceuticals (NASDAQ:MGRX) Trading 4.6% Higher – Still a Buy?

Mangoceuticals, Inc. (NASDAQ:MGRX) shares traded up 4.6% during trading on Friday . The stock traded as high as $0.4080 and last traded at $0.4028. Approximately 287,812 shares were traded during trading, a decline of 82% from the average session volume of 1,624,247 shares. The stock had previously closed at $0.3850.

Wall Street Analysts Forecast Growth

MGRX has been the subject of a number of recent research reports. Wall Street Zen raised Mangoceuticals to a “sell” rating in a research report on Saturday, July 25th. Weiss Ratings restated a “sell (e+)” rating on shares of Mangoceuticals in a research note on Wednesday, June 24th. One research analyst has rated the stock with a Sell rating, According to data from MarketBeat, the company currently has a consensus rating of “Sell”.

Mangoceuticals Stock Up 4.6%

The stock has a fifty day moving average of $0.44 and a two-hundred day moving average of $0.41. The stock has a market cap of $8.69 million, a price-to-earnings ratio of -0.40 and a beta of 2.04.

Mangoceuticals (NASDAQ:MGRX) last released its earnings results on Thursday, August 13th. The company reported ($0.09) EPS for the quarter. The business had revenue of $0.08 million during the quarter. Mangoceuticals had a negative net margin of 4,794.60% and a negative return on equity of 96.39%.

Institutional Trading of Mangoceuticals

Institutional investors have recently added to or reduced their stakes in the stock. Ikarian Capital LLC purchased a new stake in shares of Mangoceuticals during the 4th quarter worth approximately $102,000. Armistice Capital LLC acquired a new stake in shares of Mangoceuticals during the 4th quarter worth about $1,137,000. Jane Street Group LLC acquired a new stake in Mangoceuticals during the fourth quarter worth approximately $35,000. Geode Capital Management LLC boosted its holdings in shares of Mangoceuticals by 35.4% during the second quarter. Geode Capital Management LLC now owns 26,498 shares of the company’s stock worth $40,000 after purchasing an additional 6,928 shares during the last quarter. Finally, Boothbay Fund Management LLC purchased a new stake in Mangoceuticals in the 4th quarter valued at about $28,000. Hedge funds and other institutional investors own 56.72% of the company’s stock.

Mangoceuticals Company Profile

Mangoceuticals, Inc develops, markets, and sells various men's wellness products and services through a telemedicine platform in the United States. It offers erectile dysfunction (ED) products under the Mango brand and hair loss products under the Grow brand name. The company markets and sells these branded ED and hair loss products online through its website at MangoRx.com. Mangoceuticals, Inc has a marketing agreement with Marius Pharmaceuticals, LLC to market and sell KYZATREX, an oral testosterone replacement therapy product under the PRIME program.